eladocagene exuparvovec

AXP000251.1 · Viral vector gene therapy

Platform
AAV2 vector
Targets
DDC
Originator
National Taiwan University Hospital
Sponsor
PTC Therapeutics

Names

NameTypeSource
eladocagene exuparvovecpreferred namecurator
Kebilidibrandpress
Upstazabrandcurator
PTC-AADCcodecurator
AAV2-hAADCformer codecurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus 2
Strain
AAV2
Replication
non replicating
Transgenes
DDC
Route
intracerebral
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
EMAEU2022-07-18approvedUpstazaAADC deficiency with a severe phenotype in patients aged 18 months and older; authorised under exceptional circumstancessource
FDAUS2024-11approvedKebilidiAADC deficiency in adult and paediatric patientssource

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07267065AAV2-hAADC for Parkinson's Disease (PDCS-01)Not yet recruitingPhase 12026-11-012028-11-019Early Onset Parkinson Disease; Parkinson's Disease (PD)
NCT04903288A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric ParticipantsActive not recruitingPhase 22021-05-122023-05-2213AADC Deficiency
NCT02926066A Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An ExpansionCompletedPhase 22016-11-092022-01-2412Aromatic Amino Acid Decarboxylase Deficiency
NCT02852213A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric PatientsRecruitingPhase 12016-07-012027-08-3142AADC Deficiency
NCT01395641A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADCCompletedPhase 1/22014-10-222020-12-1810Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
NCT01973543Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's DiseaseCompletedPhase 12013-102020-01-2415Parkinson's Disease

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41724580Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L-Amino Acid Decarboxylase Deficiency Using an MR-Compatible Cannula: 48 Weeks of Follow-Up.Journal of inherited metabolic disease2026name in title: eladocagene exuparvovec
PMID 41212308Frameless intraputaminal delivery of gene therapy with eladocagene exuparvovec in patients with aromatic L-amino acid decarboxylase deficiency: safe and efficient results.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025name in title: eladocagene exuparvovec
PMID 34649873Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.Neurology2022cited by trial NCT01973543
PMID 34763085Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency.Molecular therapy : the journal of the American Society of Gene Therapy2022cited by trial NCT01395641
PMID 34253733Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons.Nature communications2021cited by trial NCT02852213
PMID 31918669Case report: discovery of 2 gene variants for aromatic L-amino acid decarboxylase deficiency in 2 African American siblings.BMC neurology2020name in abstract: AAV2-hAADC
PMID 30802998Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease.Annals of neurology2019cited by trial NCT01973543
PMID 30169182Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial.The Lancet. Child & adolescent health2017cited by trial NCT01395641
PMID 22424171Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.Human gene therapy2012name in abstract: AAV2-hAADC
PMID 20871425Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease.Neurosurgery2010name in abstract: AAV2-hAADC

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40991122Eladocagene Exuparvovec for the Treatment of Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd): An Economic Evaluation from a US Perspective.PharmacoEconomics2026name in title: eladocagene exuparvovec
PMID 42137299Advancing AADC deficiency therapy through MR-guided multisite delivery of AAV2-hAADC to dopaminergic and serotonergic pathways in the brainstem.Molecular therapy. Advances2026name in title: AAV2-hAADC
PMID 42389831Gene Therapy for Amino Acid Decarboxylase Deficiency: Clinical and Imaging Outcomes in a French Cohort.Movement disorders : official journal of the Movement Disorder Society2026name in abstract: eladocagene exuparvovec
PMID 42449943Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS).International journal of molecular sciences2026name in abstract: Kebilidi
PMID 39435566Optimizing the anesthetic care of patients with aromatic l-amino acid decarboxylase deficiency.Paediatric anaesthesia2025name in abstract: eladocagene exuparvovec
PMID 39743428Kebilidi (eladocagene exuparvovec-tneq).Clinical therapeutics2025name in title: eladocagene exuparvovec
PMID 39849575Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States.Health and quality of life outcomes2025name in abstract: eladocagene exuparvovec
PMID 39920752Clinically meaningful improvements after gene therapy for aromatic L-amino acid decarboxylase deficiency (AADCd) in the Peabody Developmental Motor Scale, Second Edition (PDMS-2) and correlation with Bayley-III scores and motor milestones.Orphanet journal of rare diseases2025name in abstract: eladocagene exuparvovec
PMID 40072415Eladocagene Exuparvovec for Aromatic L-Amino Acid Decarboxylase Deficiency.JAMA2025name in title: eladocagene exuparvovec
PMID 40895248The Next Frontier in Parkinson's Disease Treatment: A Narrative Review of Innovative Neurosurgical and Gene Therapy Approaches.Health science reports2025name in abstract: AAV2-hAADC
PMID 37402126Gene therapy for aromatic L-amino acid decarboxylase deficiency: Requirements for safe application and knowledge-generating follow-up.Journal of inherited metabolic disease2024name in abstract: eladocagene exuparvovec
PMID 38238766A position statement on the post gene-therapy rehabilitation of aromatic I-amino acid decarboxylase deficiency patients.Orphanet journal of rare diseases2024name in abstract: eladocagene exuparvovec
PMID 39180957Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2024name in abstract: Upstaza
PMID 36472076AAV2-hAADC (Eladocagene Exuparvovec) Biodistribution and Expression: Superiority of Intraputaminal versus Intracerebroventricular and Intrathecal (Lumbar) Routes of Administration.International journal of toxicology2023name in title: eladocagene exuparvovec
PMID 36736907AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges.Journal of controlled release : official journal of the Controlled Release Society2023name in abstract: Upstaza
PMID 37147851Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases.Movement disorders : official journal of the Movement Disorder Society2023name in abstract: eladocagene exuparvovec
PMID 37205256Intraputaminal Gene Delivery in Two Patients with Aromatic L-Amino Acid Decarboxylase Deficiency.Movement disorders clinical practice2023name in abstract: eladocagene exuparvovec
PMID 37803205Long-Term Outcomes of Eladocagene Exuparvovec Compared with Standard of Care in Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Modelling Study.Advances in therapy2023name in title: eladocagene exuparvovec
PMID 38462459Viral Vectors in Gene Replacement Therapy.Biochemistry. Biokhimiia2023name in abstract: Upstaza
PMID 36103022Eladocagene Exuparvovec: First Approval.Drugs2022name in title: eladocagene exuparvovec
PMID 39086961Strategies to improve safety profile of AAV vectors.Frontiers in molecular medicine2022name in abstract: Upstaza
PMID 34285619Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Vignette Study in France.Patient related outcome measures2021name in abstract: eladocagene exuparvovec
PMID 28166239Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.PloS one2017name in abstract: AAV2-hAADC
PMID 25860990Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.PloS one2015name in title: AAV2-hAADC
PMID 25541617SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Molecular therapy. Methods & clinical development2014name in title: AAV2-hAADC
PMID 22017504Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.Human gene therapy2012name in title: AAV2-hAADC
PMID 21430597T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery.Neurosurgery2011name in abstract: AAV2-hAADC
PMID 20531394Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.Molecular therapy : the journal of the American Society of Gene Therapy2010name in title: AAV2-hAADC
PMID 19095069Real-time MR imaging of adeno-associated viral vector delivery to the primate brain.NeuroImage2009name in abstract: AAV2-hAADC
PMID 18523450Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.Molecular therapy : the journal of the American Society of Gene Therapy2008name in abstract: AAV2-hAADC
PMID 16407771Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys.Neuroreport2006name in title: AAV2-hAADC

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01NS094292A Safety and Efficacy Study of AAV2-hAADC for AADC DeficiencyOHIO STATE UNIVERSITYBANKIEWICZ, KRYSTOF S2016–2026name in title: AAV2-hAADC
R21NS117852Validation of a single-pass surgical trajectory to enable AAV2-hAADC infusion into brainstem and mid-brain in nonhuman primateOHIO STATE UNIVERSITYBANKIEWICZ, KRYSTOF S2020–2020name in title: AAV2-hAADC

Notes

AAV2 vector carrying the DDC gene, infused into the putamen (two infusions per putamen) for aromatic L-amino acid decarboxylase deficiency. Recorded with route `intracerebral`, the spec's nearest value for an intraputaminal infusion. Upstaza in the EU, Kebilidi in the US, one program. The EU authorisation was granted under exceptional circumstances.

How to cite

eladocagene exuparvovec (AXP000251.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000251.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.